Department of Otolaryngology, Queen's Hospital, Romford, UK.
J Laryngol Otol. 2022 May;136(5):466-468. doi: 10.1017/S0022215122000597. Epub 2022 Feb 28.
In a bid to end the ongoing coronavirus disease 2019 pandemic, many countries, including the UK, have rolled out mass immunisation programmes. While considered generally safe and effective, vaccines against coronavirus disease 2019 have been reported to be associated with rare and potentially adverse reactions and side effects.
This paper reports an unusual case of a patient who developed a unilateral vocal fold paralysis shortly after receiving the first dose of the Oxford-AstraZeneca ChAdOx1 nCov-19 vaccine.
To our knowledge, this is the first reported case of vocal fold paralysis following administration of the Oxford-AstraZeneca vaccine. The authors support the position that currently approved coronavirus disease 2019 vaccines remain safe and effective; however, further surveillance and vigilance using real-world data are highly encouraged.
为了结束当前的 2019 冠状病毒病大流行，包括英国在内的许多国家都推出了大规模免疫接种计划。尽管被认为通常是安全有效的，但 2019 冠状病毒病疫苗已被报告与罕见且可能的不良反应和副作用有关。
本文报告了一例不寻常的病例，一名患者在接种第一剂牛津-阿斯利康 ChAdOx1 nCov-19 疫苗后不久出现单侧声带麻痹。
据我们所知，这是首例接种牛津-阿斯利康疫苗后发生声带麻痹的报告。作者支持这样的观点，即目前批准的 2019 冠状病毒病疫苗仍然是安全有效的；然而，强烈鼓励使用真实世界数据进行进一步的监测和警惕。
